MX2018009405A - Sintesis y composicion de bibliotecas de rapafucina. - Google Patents

Sintesis y composicion de bibliotecas de rapafucina.

Info

Publication number
MX2018009405A
MX2018009405A MX2018009405A MX2018009405A MX2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A MX 2018009405 A MX2018009405 A MX 2018009405A
Authority
MX
Mexico
Prior art keywords
synthesis
rapafucin
libraries
composition
compounds
Prior art date
Application number
MX2018009405A
Other languages
English (en)
Spanish (es)
Inventor
Liu Jun
Wang Jingxin
Guo Zufeng
hong Sam
Liu Wukun
Peng Hanjing
Das Manisha
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2018009405A publication Critical patent/MX2018009405A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Peptides Or Proteins (AREA)
MX2018009405A 2016-02-04 2017-02-03 Sintesis y composicion de bibliotecas de rapafucina. MX2018009405A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291437P 2016-02-04 2016-02-04
PCT/US2017/016481 WO2017136708A1 (en) 2016-02-04 2017-02-03 Synthesis and composition of rapafucin libraries

Publications (1)

Publication Number Publication Date
MX2018009405A true MX2018009405A (es) 2018-11-09

Family

ID=59501078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009405A MX2018009405A (es) 2016-02-04 2017-02-03 Sintesis y composicion de bibliotecas de rapafucina.

Country Status (8)

Country Link
US (1) US10662220B2 (https=)
EP (1) EP3411413A4 (https=)
JP (2) JP6891183B2 (https=)
CN (1) CN108713028B (https=)
AU (1) AU2017214550B2 (https=)
CA (1) CA3013589A1 (https=)
MX (1) MX2018009405A (https=)
WO (1) WO2017136708A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
DK3269809T3 (da) 2015-03-13 2022-09-12 Chugai Pharmaceutical Co Ltd MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
MX2018009405A (es) * 2016-02-04 2018-11-09 Univ Johns Hopkins Sintesis y composicion de bibliotecas de rapafucina.
US10774110B2 (en) * 2016-02-04 2020-09-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
CA3013783A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapaglutins, novel inhibitors of glut and use thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
JP7232758B2 (ja) * 2017-06-09 2023-03-06 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
WO2020163594A1 (en) 2019-02-07 2020-08-13 The Regents Of The University Of California Immunophilin binding agents and uses thereof
KR20210139366A (ko) * 2019-03-15 2021-11-22 추가이 세이야쿠 가부시키가이샤 방향족 아미노산 유도체의 제조 방법
WO2021067405A1 (en) * 2019-10-01 2021-04-08 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
TW202126323A (zh) 2019-10-01 2021-07-16 約翰斯赫普金斯大學 雷帕弗辛(Rapafucin)衍生化合物及其使用方法
CN120271673A (zh) * 2024-01-08 2025-07-08 重庆医科大学 一种化合物、包含其的药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CN1187127A (zh) * 1995-06-07 1998-07-08 吉尔福特药品有限公司 旋转异构酶活性抑制剂
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US6984635B1 (en) * 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
AU766513B2 (en) * 1998-02-13 2003-10-16 Board Of Trustees Of The Leland Stanford Junior University Novel dimerizing agents, their production and use
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2010004304A1 (en) 2008-06-17 2010-01-14 Biotica Technology Limited Novel compounds and methods for their production
EP2646440A4 (en) * 2010-11-30 2014-06-18 Univ Johns Hopkins CYCLIC HYBRID LIBRARIES AND SCREENS FOR THIS
EP2607352A1 (en) * 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
WO2014201405A1 (en) * 2013-06-14 2014-12-18 The Board Of Regents Of The University Of Texas System Novel allosteric inhibitors of proteasome and methods of use thereof
MX2018009405A (es) 2016-02-04 2018-11-09 Univ Johns Hopkins Sintesis y composicion de bibliotecas de rapafucina.

Also Published As

Publication number Publication date
EP3411413A1 (en) 2018-12-12
US10662220B2 (en) 2020-05-26
EP3411413A4 (en) 2019-09-18
AU2017214550A1 (en) 2018-08-16
JP2021138726A (ja) 2021-09-16
CN108713028B (zh) 2021-12-28
CA3013589A1 (en) 2017-08-10
JP2019510738A (ja) 2019-04-18
AU2017214550B2 (en) 2024-03-07
JP7158532B2 (ja) 2022-10-21
CN108713028A (zh) 2018-10-26
WO2017136708A1 (en) 2017-08-10
US20190092808A1 (en) 2019-03-28
JP6891183B2 (ja) 2021-06-18

Similar Documents

Publication Publication Date Title
MX2018009405A (es) Sintesis y composicion de bibliotecas de rapafucina.
IL286833A (en) Compositions containing brazzein
IL282682A (en) Improved synthesis of key intermediate of kras g12c inhibitor compound
DK4021901T3 (da) Substituerede pyridopyrimidinonylforbindelser som er nyttige som t-celleaktivatorer
PL3844147T3 (pl) Związki chemiczne
DK4165024T3 (da) Cyclobutyldihydroquinolinsulfonamid-forbindelser
EP4129997A4 (en) Octahydropyrazinodiazanaphthyridine dione compounds
CO2019003709A2 (es) Conjugados de pirrolobenzodiazepina
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
EA201992235A1 (ru) Синтез ингибитора mcl-1
PT4058453T (pt) Síntese melhorada de composto inibidor de kras g12c
CL2018003132A1 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
EP3842412A4 (en) BIODEGRADABLE COMPOUND, LIPID PARTICLES, COMPOSITION WITH LIPID PARTICLES AND KIT
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
IL310528A (en) Pyrazolopyridinone compounds
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
DK3866931T3 (da) Forbindelser indeholdende deuterium
DK3648743T3 (da) Pressede tabletter, der omfatter nitrooxyforbindelser
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
PL3405178T3 (pl) Preparaty/kompozycje zawierające inhibitor btk
DK4320112T3 (da) Pyridinylsubstituerede oxoisoindolinforbindelser
DK3681885T3 (da) Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.